Aurinia Pharmaceuticals Inc.
AUPH
16.35 $
1 Tag: N/A
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer AUPH
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Aktuelle News
-
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
Vorschau anzeigen
Aurinia Pharmaceuticals Inc. recently reported second-quarter 2026 results showing higher revenue and earnings year over year, reiterated its 2026 revenue and net product sales guidance, completed a large share buyback program, and finalized a settlement with Teva Pharmaceuticals that delays U.S. generic voclosporin entry until at least December 7, 2036. The Teva settlement meaningfully strengthens Aurinia’s intellectual property protection around voclosporin, potentially extending its U.S...
-
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
Vorschau anzeigen
Is AUPH a good stock to buy? We came across a bullish thesis on Aurinia Pharmaceuticals Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AUPH. Aurinia Pharmaceuticals Inc.’s share was trading at $18.62 as of June 24th. AUPH’s trailing and forward P/E were 8.27 and 23.42 respectively according to Yahoo […]
-
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
Vorschau anzeigen
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
-
Aurinia Pharmaceuticals and Four More Stocks See Activist Action
Vorschau anzeigen
Activists also report to the SEC on Victoria’s Secret, Dell Technologies, Valaris, and Universal Technical Institute.
-
Aurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 Million
Vorschau anzeigen
This biopharma firm, focused on therapies for autoimmune diseases, reported a recent insider buy amid a year of strong share performance.